Introducing the MyoStrain® Test

Enabling a Rapid & Quantitative Heart Health Assessment to Manage Asymptomatic Patient Populations

About half of US adults have some form of cardiovascular disease, yet, it is often not until symptoms of cardiac damage appear that a patient is diagnosed with heart failure. This is because today's diagnostic standard cannot directly quantify the asymptomatic effects of disease, drugs and treatment on the heart. MyoStrain provides a uniquely rapid and accurate assessment to help physicians quantify asymptomatic changes in heart function early, treat patients proactively and manage individualized cardiac care across large at-risk populations.

Quantifying the Effects of Disease, Drugs & Treatment on the Heart in Under 10 Minutes

The unique and proprietary MyoStrain® test quantifies segmental intra-myocardial strain to directly quantifies changes in contraction across 48 segments. This provides physicians with the sensitivity and accuracy needed to detect the early progression of heart dysfunction and initiate early intervention. MyoStrain is FDA-cleared and CE-mark certified, providing novel cardiac information–as well as superior speed, ease and accuracy–to help inform clinical decisions and improve patient outcomes.

Comprehensive Patient Reporting Simplified into One MyoHealth™ Score

The MyoStrain report provides physicians and patients with a MyoHealth Score, a quantitative and holistic measure of patient heart health representing the total percentage of normally functioning myocardium.

Calculated by dividing the number of left-ventricular segments with normal function by the total number of left-ventricular segments, the MyoHealth score provides a baseline of patient heart health. Physicians are able to identify patients who are at risk of adverse cardiac events early and initiate proactive treatment intervention to mitigate cardiac damage and protect the heart long-term.

Superior Speed

+ 10-minute exam time
+ Twelve-heartbeat MRI scan
+ Realtime strain encoding
+ Generates report immediately
+ Rapid exam times enables higher scan volumes and improved clinical efficiencies

Superior Accuracy

+ Quantifies contractility across 48 segments of LV and RV
+ Provides longitudinal and circumferential strain, global strain, and other traditional metrics
+ Consistent results independent of user and scanner type

Immense Clinical Value

+ Helps physicians to detect at-risk cardiac patients before symptoms occur
+ Helps physicians optimize treatment by monitoring the individual effects over time
+ Helps physicians to reduce hospitalizations, medications and mortality

Enhanced Patient Experience

+ Simple and easy-to-understand heart health score
+ Safe and non-invasive procedure
+ No contrast agents, exposure to radiation, or breath hold required

MyoStrain and the MyoHealth Score Enables Physicians to Classify and Risk-Stratify Asymptomatic Cardiac Patients According to ACC/AHA- Standardized Heart Failure Stages

A MyoHealth baseline provides a longitudinal perspective of the patient's heart health. Each score can be plotted along a progressive dysfunction curve and serves as a powerful clinical tool to help quantify how the patient's heart health changes over time. This may help to significantly improve patient outcomes, as physicians are able to focus on individualizing treatment to the patient based on their response to therapy and monitor the heart long-term.

Published in the Journal of the American college of cardiology, the diagram above demonstrates MyoStrain's ability to accurate detect, risk-stratify and classify asymptomatic heart failure patients, highlighting MyoHealth (% normal myocardium) as a far more sensitive cardiac risk marker compared to traditional standard of care metrics such as LVEF. The diagram further illustrates a proactive diagnostic window for physicians to manage preventative treatment before damage occurs.

Become a MyoStrain-Certified Physician

Become certified and learn how to refer patients to receive MyoStrain, read MyoStrain reports and make informed clinical decisions to transform your cardiac practice

About the MyoStress™ Test

MyoStress™ provides a rapid, safe and "needle-free" 15-minute stress test to designed to help physicians detect myocardial ischemia

About MyoHeath™ MD

The MyoHealth MD mobile app is a simple and intuitive tool designed to help physicians better understand their patients' heart health

About Segmental Strain

MyoStrain's unique and proprietary segmental strain analysis provides novel cardiac information about patient heart health

MyoStrain Research Highlights

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
Hyperventilation/Breath-Hold Maneuver to Detect Myocardial Ischemia by Strain-Encoded CMR: Diagnostic Accuracy of a Needle-Free Stress Protocol
This article demonstrates MyoStrain’s speed and sensitivity to successfully measure cardiac stress during a safe, simple hyperventilation breathing maneuver. Performed without any pharmacological or physical stress protocols, this new technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease.
This is some text inside of a div block.
April 15, 2021
JACC: Cardiovascular Imaging
Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis
The study compared MyoStrain’s ability to quantify and differentiate asymptomatic patients based on their cardiac risk versus traditional ejection faction, reiterating the technology's potential as a critical cardiac risk stratification tool enabling clinicians to identify at-risk patients early for individualized preventative treatment.
This is some text inside of a div block.
April 5, 2021
Journal of Cardiovascular Magnetic Resonance

Latest MyoStrain Presentations

VCOS 2020 Satellite Symposium: How MyoStrain® Quantifies Segmental Myocardial Strain
Nael Osman, PhD
|
Myocardial Solutions, Inc., Johns Hopkins University
October 1, 2020
VCOS 2020 Satellite Symposium: Cardiac MRI in Cardio-Oncology: Strain at its Best Fidelity (MyoStrain®)
Daniel J Lenihan, MD, FACC, FESC
|
Washington University School of Medicine in St. Louis
October 1, 2020
VCOS 2020 Satellite Symposium: Cardiac Magnetic Resonance in Cardio-Oncology: The Role of Myocardial Strain (Takeaways)
Alexander Lyon, MD, PhD
|
Royal Brompton Hospital, Imperial College London
October 1, 2020